Date: 2011-05-11
Type of information: Fundraising
Company: Axelar (Sweden)
Investors: syndicate of investors including Karolinska Development (Sweden)
Amount: SEK 123 milion (€ 13.7 million)
Funding type: financing round
Planned used: The funds will be used to complete its coming Phase II program in patients suffering from non-small cell lung cancer (NSCLC).
Others: Axelar, a Karolinska Development portfolio company, has secured SEK 123 milion (€ 13.7 million) which will allow Axelar to complete its coming Phase II program in patients suffering from non-small cell lung cancer (NSCLC). Data from the ongoing Phase I/II trial will be presented later this year. Axelar recently reported promising interim data from the first part of the Phase I/II study. AXL1717 has shown excellent tolerability and promising survival data in NSCLC patients. More than 45 patients have been treated so far.
Therapeutic area: Cancer - Oncology
